Oslo, 16 February 2022 - Navamedic ASA (OSE: NAVA) today announces the launch of
SmectaGO[®] for sale through pharmacies in Norway, Sweden, Finland and Denmark
this spring. SmectaGO[®] is a unique product developed to treat acute and
chronic diarrhea in adults and children above 8 years. The launch is part of a
long-term agreement with the well known French pharmaceutical corporation Ipsen
Consumer HealthCare wherein Navamedic has been appointed the exclusive partner
in the Nordics.

"Diarrhea and other gastro conditions are very common, but in the Nordics, we
know from research that only 20 percent of those suffering from such conditions
seek treatment. We can improve many people's lives through driving awareness and
knowledge of treatment options. With our local insights and market access,
Navamedic intends to drive the development of this category in the Nordics, and
with SmectaGO®, we can offer a unique product to Nordic consumers. SmectaGO® is
already well established on the European continent and has been a favourite for
a long time for the treatment of diarrhea. We are honored that Ipsen Consumer
HealthCare selected Navamedic as their Nordic partner for this product range,"
says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.

"This cooperation embodies the purpose of our Consumer HealthCare Division,
which is to bring people across the world care and comfort in their daily lives
with healthcare solutions they can trust. Indeed, it is a great opportunity to
touch more patients with an innovative and proven effective product against
diarrhea." says Djamel Oulali, Senior Director Export in Ipsen Consumer
HealthCare.

SmectaGo® is a ready-to-drink suspension for use in the treatment of acute
diarrhea in adults and children above 8 years of age. The main component of the
product is diosmectite, a natural clay that helps in the inhibition and
treatment of diarrhea and in relieving abdominal pain.

Diarrhea is a common disease that affects adults and children from time to time,
and some patients suffer from chronic conditions. In Norway alone, intestinal
disorders accounts for up to 5000 consultations per week with general
practicioners. SmectaGO® is a product that can be bought in the pharmacies
without any prescription, and is different from any other product on the market
and uniquely characterized by its "stop and treat" mode of action:

  · Ready to drink for a fast intake on the go
  · Removes the toxins and germs
  · Helps to repair intestinal damage
  · Relieves abdominal pain

The agreement with Ipsen Consumer HealthCare will strengthen Navamedic's
position in the gastroenterology category, which represents a significant growth
potential in the Consumer Health segment where patients can find approved
treatment options without prescriptions in the pharmacies. As part of the
agreement, Navamedic will also take over the distribution and sales in Sweden of
Forlax®, a prescription drug for the treatment of constipation in adults and
children aged 8 years and above.

"Navamedic has a target of 20 percent annual organic growth and the mid-term
ambition of building a NOK 500 million company, as we continue to accelerate
growth through launch of new products and push for growth in our existing
portfolio. The launch of SmectaGO® is a perfect example on how we like to
develop categories and drive growth," says Kathrine Gamborg Andreassen, CEO of
Navamedic ASA.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47917 62 842

E-mail: lars.hjarrand@navamedic.com

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
visitwww.navamedic.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.